Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Acute Lymphocytic Leukemia - Therapy, Excluding Transplantation Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium

Yoav H. Messinger, MD1, Paul S. Gaynon, MD2, Elizabeth Raetz, MD3, Raymond Hutchinson, MD, MS4*, Steven DuBois, MD5*, Julia Glade Bender, MD6*, Richard Sposto, PhD7*, Jeannette van der Giessen, BA, CCRP7*, Elena Eckroth, CCRC7* and Bruce C. Bostrom, MD8

1Children's Hospitals and Clinics, Saint Paul, MN
2Pediatric Hematology/Oncology, Childrens Hospital of Los Angeles, Los Angeles, CA
3Pediatric Hematology/Oncology, New York University Medical Center, New York, NY
4Pediatric Hematology/Oncology, C.S. Mott Children's Hospital, Ann Arbor, MI
5Pediatric Hematology/Oncology, UCSF School of Medicine, San Francisco, CA
6Division of Pediatric Oncology, Columbia Presbyterian College of Physicians & Surgeons, New York, NY
7USC-CHLA Institute for Pediatric Clinical Research, Childrens Hospital Los Angeles, Los Angeles, CA
8Children's Hospitals & Clinics of Minnesota, Minneapolis, MN

In Vivo Mobilization of Leukemic Human Precursor-B-ALL Cells by the CXCR4-Antagonist AMD3100 Is Via Secretion of SDF-1 and Synergistically by Catecholamine Action

Eike C. Buss, MD1*, Alexander Kalinkovich, MD, PhD1*, Amir Schajnovitz, MSc1*, Orit Kollet, PhD1, Ayelet Dar, PhD1*, Melania Tesio, PhD1*, Stefan Fruehauf, MD2*, Marc Hotfilder, PhD3*, Anthony D. Ho, MD4, Leonard D. Shultz5 and Tsvee Lapidot, PhD1

1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
2Zentrum für Tumordiagnostik und Therapie, Paracelsus-Klinik, Osnabrück, Germany
3Department of Pediatric Hematology and Oncology, University Childrens's Hospital, Münster, Germany
4Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
5The Jackson Laboratory, Bar Harbor, ME

PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Francesca Chiarini, BS1*, Federica Fala, PhD1*, Francesca Ricci, BS2*, PierLuigi Tazzari, MD2*, Annalisa Astolfi, PhD3*, Andrea Pession, MD, PhD3, James McCubrey, PhD4 and Alberto M. Martelli, MD1

1Dept. of Human Anatomical Sci., Univ. of Bologna, Bologna, Italy
2Transfusion Center, Policlinico S.Orsola-Malpighi, Bologna, Italy
3Pediatric Oncology and Haematology Unit, University of Bologna, Bologna, Italy
4School of Medicine, East Carolina University, Greenville, NC

Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target

Valerie I. Brown, MD, PhD1, Cecilia Sheen2*, Jessica Hulitt2*, Theresa Ryan2*, Laura DiNardo2*, David Barrett, MD, PhD3*, David T. Teachey, MD3*, David J. Bearss, PhD4*, Gregory I. Berk, MD5 and Stephan A. Grupp, MD, PhD6

1Oncology, Children's Hosp. of Philadelphia and the Univeristy of Pennsylvania School of Medicine, Philadelphia, PA
2Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
3Oncology and Hematology, Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, PA
4Discovery Research, SuperGen, Inc., Dublin, CA
5Clinical Research, SuperGen, Inc., Dublin, CA
6Oncology and Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, PA

Tubacin, An Inhibitor of HDAC6, Induces Apoptosis of Acute Lymphoblastic Leukemia Cells in Vitro and in Vivo through a Na+/K+ATPase-Dependent Pathway

Agustin Rodriguez-Gonzalez, Ph.D.1*, Tiffany Simms-Waldrip, M.D.2*, Alan K. Ikeda, M.D.2*, Tara Lin, M.D.3*, Brett Lomenick2*, Grace Aldana-Masangkay2*, Ralph Mazitschek, Ph.D.2*, James Bradner4, Cecilia Fu, M.D.2 and Kathleen M. Sakamoto, M.D., Ph.D.1

1Pediatrics, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA
2Pediatrics A2-412 MDCC, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA
3Hematology-Oncology, Louisiana State University Health Sciences Center, New Orleans, LA
4Broad Institute of Harvard and MIT, Boston, MA

Toxicities in Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Regimens Using Pegasparaginase

Michael Rytting, M.D.1, Marc Earl, PharmD2*, Dan Douer, MD3, Brenda Muriera, RN1*, Anjali Advani, MD4 and Archie Bleyer, MD5*

1Pediatric Hematology-Oncology, M.D. Anderson Cancer Center, Houston, TX
2Pediatric Hematology-Oncology, The Cleveland Clinic, Cleveland,, OH
3Kenneth Norris Jr. Comp. Cancer Ctr., Univ. of Southern California, Los Angeles, CA
4Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
5St Charles Medical Center, Bend, OR

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells

Irene Homminga, MD1*, Christian M Zwaan, MD, PhD1, Chantal Y. Manz, PhD2, Shanta Bantia, PhD3*, Cynthia Parker3*, Jessica Buijs-Gladdines1*, Wilco Smits1*, Martin A. Horstmann, MD4*, Rob Pieters, MD, PhD1* and Jules P.P. Meijerink, MSc, PhD1*

1Dept. of Pediatric Oncology/Hematology, ErasmusMC Rotterdam-Sophia Children's Hospital, Rotterdam, Netherlands
2Mundipharma International Ltd, Cambridge, United Kingdom
3BioCryst Pharmaceuticals Inc, Birmingham, AL
4Pediatric Hem., Hamburg Univ. Med. Ctr., Hamburg, Hamburg, Germany

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 /MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study

Max Topp, MD1*, Nikola Goekbuget, MD2*, Peter Kufer, MD3*, Gerhard Zugmaier, MD3*, Evelyn Degenhard3*, Svenja Neumann, MD4*, Heinz A Horst, MD4*, Andreas Viardot, MD5*, Mathias Schmid, MD5*, Oliver G. Ottmann, MD2*, Margit Schmidt, PhD3*, Carsten Reinhardt, MD3*, Patrick A Baeuerle, PhD3*, Dirk Nagorsen, MD3*, Dieter Hoelzer, MD, PhD2 and Ralf C. Bargou, MD1*

1Hematology & Oncology, Medical Center University of Wuerzburg, Wuerzburg, Germany
2Hematology, J.W. Goethe University Hospital, Frankfurt/M, Germany
3Micromet AG, Munich, Germany
4II. Medizinische- und Poliklinik, University Hospital Schleswig-Holstein Kiel, Kiel, Germany
5Hematology, University Hospital Ulm, Ulm, Germany

General Condition and Early Complications Have in Addition to Disease-Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15-55 years)

Nicola Goekbuget, MD1, Renate Arnold, MD, PhD2*, Anja Baumann, MD3*, Joachim Beck, MD4*, Helmut Diedrich, MD5*, Mathias Freund, MD, PhD6, Andreas Hüttmann, MD, PhD7*, Michael Kneba, MD, PhD8*, Karl Anton Kreuzer, MD9*, Lothar Leimer, MD10*, Thomas Lipp, MD11*, Dorle Messerer12*, Ralph Naumann, MD, PhD13*, Albrecht Reichle, MD, PhD14*, Harald Rieder, MD, PhD15*, Kerstin Schäfer-Eckart, MD16*, Marc Schmalzing, MD17*, Mathias Schmid, MD, PhD18*, Norbert Schmitz, MD, PhD19, Hubert Serve, MD, PhD20*, Matthias Stelljes, MD21*, Eckhard Thiel, MD, PhD22 and Dieter Hoelzer, MD, PhD23

1Medical Department II, J.W.Goethe University, Frankfurt, Germany
2Campus Virchow-Klinikum, University Hospital Charité, Berlin, Germany
3University Hospital München-Großhadern, München, Germany
4University Hospital, Mainz, Germany
5Medizinische Hochschule, Hannover, Germany
6Division of Hematology and Oncology, University of Rostock, Germany
7University Hospital, Essen, Germany
8University Hospital, Kiel, Germany
9University Hospital, Cologne, Germany
10Robert Bosch Krankenhaus, Stuttgart, Germany
11Klinikum München-Schwabing, München, Germany
12Ibe, University of München, München, Germany
13University of Dresden, Dresden, Germany
14University of Regensburg, Regensburg, Germany
15Cytogenetics, University of Düsseldorf, Düsseldorf, Germany
16Klinikum Nürnberg-Nord, Nürnberg, Germany
17University Hospital, Tuebingen, Germany
18University Hospital, Ulm, Germany
19Hematology and Stem Cell Transplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany
20Medical Department II, University Hospital of Frankfurt, Frankfurt, Germany
21University Hospital, Münster, Germany
22Medizinische Klinik III, Charite Campus Benjamin Franklin, Berlin, Germany
23J.W. Goethe University Hospital, Frankfurt, Germany

Sustained and Prolonged Asparagine Depletion by Multiple Doses of Intravenous Pegylated Asparaginase in the Treatment of Adults with Newly Diagnosed Acute Lymphoblastic Leukemia

Dan Douer1, Kristy Watkins1*, Lisa Mark1*, Mohrbacher Ann1*, Allen S Yang1* and Vassilios I Avramis2*

1Kenneth Norris Jr. Comp. Cancer Ctr., Univ. of Southern California, Los Angeles, CA
2Hematology/Oncology, Childrens Hospital Los Angeles, Los Angeles, CA

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (ALL)

Deborah A. Thomas, MD1, Hagop M. Kantarjian, MD1*, Jorge Cortes, MD2, Stefan Faderl, MD2, William G. Wierda, MD, PhD3*, Farhad Ravandi, MBBS4, Maria Alma Rodriguez, MD5, Luis Fayad, MD6 and Susan O'Brien, M.D.7

1Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2M.D. Anderson Cancer Center, Houston, TX
3MD Anderson Cancer Centre, University of Texas, Houston, TX
4Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX
6MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens

Deborah A. Thomas, MD1, Susan O'Brien, M.D.2, Michael Rytting, M.D.3, Stefan Faderl, MD4, Jorge Cortes, MD4, William G. Wierda, MD, PhD5*, Farhad Ravandi, MBBS6 and Hagop M Kantarjian7

1Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
3Pediatric Hematology-Oncology, M.D. Anderson Cancer Center, Houston, TX
4M.D. Anderson Cancer Center, Houston, TX
5MD Anderson Cancer Centre, University of Texas, Houston, TX
6Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
7The University of Texas M. D. Anderson Cancer Center, Houston, TX

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Deborah A. Thomas, MD1, Hagop Kantarjian, MD2*, Stefan Faderl, MD3, William G. Wierda, M.D., Ph.D4, Alessandra Ferrajoli, MD5*, Jan A. Burger, MD, PhD6, Jorge Cortes, MD3, Charles A. Koller, MD7*, Gautam Borthakur, MBBS8*, Zeev Estrov9*, Marina Konopleva, MD, PhD1, Farhad Ravandi, MBBS10, Guillermo Garcia-Manero, MD2 and Susan O'Brien, M.D.8

1Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
3M.D. Anderson Cancer Center, Houston, TX
4Leukemia, UT M. D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, M.D. Anderson Cancer Ctr., Houston, TX
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7Leukemia Department, University of Texas - M.D. Anderson Cancer Center, Houston, TX
8Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
9Leukemia, UT, M.D. Anderson Cancer Center, Houston, TX
10Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

*signifies non-member of ASH